0001415889-24-019676.txt : 20240717 0001415889-24-019676.hdr.sgml : 20240717 20240717164535 ACCESSION NUMBER: 0001415889-24-019676 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240715 FILED AS OF DATE: 20240717 DATE AS OF CHANGE: 20240717 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RENTON HOLLINGS CENTRAL INDEX KEY: 0001187333 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37985 FILM NUMBER: 241122723 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANAPTYSBIO, INC CENTRAL INDEX KEY: 0001370053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 203828755 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-362-6295 MAIL ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYSBIO INC DATE OF NAME CHANGE: 20080828 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC DATE OF NAME CHANGE: 20060724 4 1 form4-07172024_080731.xml X0508 4 2024-07-15 0001370053 ANAPTYSBIO, INC ANAB 0001187333 RENTON HOLLINGS C/O ANAPTYSBIO, INC. 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 true false false false 1 Common Stock 2024-07-15 4 M 0 10000 6.93 A 11950 D Common Stock 2024-07-15 4 S 0 7103 30.5038 D 4847 D Common Stock 2024-07-15 4 S 0 2897 30.9817 D 1950 D Common Stock 6.93 2024-07-15 4 M 0 10000 0 D 2025-07-05 Common Stock 10000 30925 D The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options before their expiration. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.91 to $30.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.92 to $31.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option grant was issued on July 6, 2015, is fully vested and exercisable until its expiration date of July 5, 2025. /s/ Eric Loumeau, Attorney-in-Fact 2024-07-17